Hercules Capital (HTGC) Stock Looks Cheap On Fair Value And Earnings
Hercules Capital, Inc. HTGC | 0.00 |
Hercules Capital stock is coming off a solid 5 year return, yet current checks suggest the market price may still sit below what its fundamentals imply. At the last close of US$15.94, both the intrinsic value estimate from the Excess Returns model and the earnings multiple view point to a market that may be underpricing the company.
- Hercules Capital has returned 60.3% over the past 5 years, which puts recent short term weakness into a longer term context of gains.
- Future lending growth and credit quality can be key for sustaining cash flows, while any deterioration in portfolio performance or higher funding costs may weigh on what investors are willing to pay for the stock.
- The company screens as undervalued across 6 of 6 valuation checks, which suggests the broader set of metrics leans cheap rather than fully priced.
The issue now is whether Hercules Capital's current discount to the intrinsic value estimate and market multiples leaves enough margin of safety for investors who are focusing on valuation.
Is Hercules Capital Still Cheap on Excess Returns?
The Excess Returns model looks at how much profit Hercules Capital is expected to earn on its equity above the required return. For Hercules Capital, the framework starts with a Book Value of $12.08 per share and a Stable EPS estimate of $1.87 per share, based on return on equity inputs from 4 analysts. Against a Cost of Equity of $1.07 per share, this points to an Excess Return of $0.80 per share and an Average Return on Equity of 15.98%, anchored to a Stable Book Value of $11.71 per share from the past 5 years.
When these excess profits are capitalised, the Excess Returns model arrives at an intrinsic value of about $25.84 per share. That sits above the recent share price of $15.94, which implies a discount of roughly 38.3%. On these assumptions, the market appears to be pricing Hercules Capital below what its level of excess profitability would support.
On the Excess Returns view, Hercules Capital stock currently screens as undervalued versus its estimated intrinsic value.
Our Excess Returns analysis suggests Hercules Capital is undervalued by 38.3%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks.
Does Hercules Capital Look Undervalued on Earnings?
The P/E multiple suits Hercules Capital because earnings are a primary driver of how investors usually think about business development companies. Hercules Capital trades on a P/E of 8.9x, which sits well below the Capital Markets industry average of 37.2x and the peer group average of 26.8x. That places the stock at a sizeable discount to many listed finance peers on this simple earnings yardstick.
The tailored fair P/E ratio for Hercules Capital is 12.2x, based on factors such as its sector, size and risk profile. The current P/E of 8.9x sits below this level, which suggests the market is pricing Hercules Capital’s earnings more cautiously than the model implies. For investors who lean on earnings based valuation, the gap between today’s multiple and the fair ratio indicates potential for a higher valuation if sentiment toward the company improves.
On the market multiple view, Hercules Capital stock currently appears undervalued relative to what its earnings profile would typically support.
The Hercules Capital Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Hercules Capital pick up from this valuation gap and spell out which future paths in growth, margins and earnings would justify a higher or lower share price than today. Instead of stopping at a single model output, they unpack the set of business assumptions that number rests on so you can monitor how Hercules Capital's actual progress lines up with the scenario that is currently implied. These Narratives sit on Simply Wall St's Community page and provide a structured way to think about what would need to change for the stock's valuation to shift meaningfully.
Community views on Hercules Capital sit on a wide spectrum, from a meaningful undervaluation gap to a case that sees the stock roughly fairly valued once risks are factored in.
Bull case: 18% undervalued
"Sustained expansion in the technology and life sciences sectors continues to drive record growth in new loan originations and fundings for Hercules, supporting robust revenue and net investment income growth into 2026..."
Bear case: roughly fairly valued
"Hercules Capital may face pressure on future core yields, which have already declined from 12.9% in Q4 to 12.6% in Q1, due to declining base rates and spread compression, potentially impacting revenue growth and net income..."
Do you think there's more to the story for Hercules Capital? Head over to our Community to see what others are saying!
The Bottom Line
Hercules Capital screens as undervalued on both the Excess Returns intrinsic value estimate and on earnings-based market multiples, which point in the same direction. Together, those signals suggest the current discount reflects caution rather than an obviously stretched valuation. What really decides the outcome from here is whether Hercules Capital can sustain the level of excess profitability that underpins the intrinsic value estimate while keeping credit quality and funding costs under control. The key question for you is whether that discount represents an opportunity or a fair reflection of the risks tied to the lending portfolio and future earnings path.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
